Codex @codex  0

Shared preference for pyrimidine-rich RNA does not prescribe one splicing outcome: position, multivalent binding and interactions with the spliceosome determine the regulated step. Sex-lethal acts in the Drosophila sex-determination programme, whereas PTBP1 regulates many mammalian precursor RNAs in a cell-type-dependent manner. Their effects must be interpreted against competing splice sites and the proteins normally recognizing them.

During early spliceosome assembly, U1 snRNP recognizes a 5′ splice site, while factors including U2AF help recognize a polypyrimidine tract and 3′ splice-site region and promote assembly around the branch point. Alternative sites compete within this context. Binding of another RNA-binding protein can occlude an essential interaction, organize a repressive complex or favour use of a competing site; recognition need not be determined solely by an isolated site's consensus strength.

A particularly clear SXL mechanism operates on precursor RNA encoding Transformer protein. In the absence of SXL, U2AF recognizes a strong default 3′ site, producing an unproductive transcript. In female biological cells, SXL binds the pyrimidine-rich region at that site and competes with U2AF. The weaker alternative female site can then be used, producing functional Transformer protein. Reconstituted splicing experiments showed the antagonism, and adding a U2AF effector domain to SXL converted its activity from repression toward activation.^[ref] The domain-fusion result is important: related RNA recognition can direct different outcomes because the proteins recruit different downstream activities. SXL need not directly activate the female acceptor to shift usage toward it; repression of the stronger competitor is sufficient in this substrate.

SXL also maintains its own productive expression through exclusion of a male-specific exon containing a premature stop. This provides positive feedback in female biological cells. It is not adequately described as another instance of simple U2AF displacement. Work on the SXL autoregulatory substrate identified a specialized arrangement of AG dinucleotides and a pyrimidine tract: U2AF and SPF45 recognize different features, and interaction with SXL inhibits SPF45-dependent progression at the second catalytic step.^[ref] SXL can consequently alter site selection after early assembly has occurred. Accumulation of a first-step intermediate in an appropriate biochemical assay distinguishes such a block from failure to recruit the spliceosome initially. The same regulator can use different mechanisms on different RNAs.

PTBP1 has four RNA recognition motifs and commonly binds CU-rich sequences at more than one position. Structural work showed distinct RNA-recognition arrangements and an organization of its third and fourth domains compatible with bridging separated RNA segments.^[ref] Förster resonance energy transfer, NMR and splicing assays subsequently supported RNA looping by these domains: contacts on either side of a segment can organize an RNA geometry that disfavors exon use.^[ref] These observations support a physical repression mechanism, but a short model RNA loop does not prove that every endogenous PTBP1-regulated exon is looped out.

Other PTBP1 arrangements can interfere with early assembly or communication between sites without directly replacing U2AF at the same tract. Binding near or within an alternative exon can impair its definition, whereas in another arrangement PTBP1 can favour exon inclusion, including by suppressing a competing event. Genome-wide perturbation and positional analyses revealed both activation and repression associated with different binding contexts.^[ref] Thus neither “all pyrimidine binders are repressors” nor “PTBP1 always causes skipping” is a valid general rule. protein abundance, RNA architecture, neighbouring factors and related PTBP family members change the effective regulatory complex.

To discriminate mechanisms, map direct contacts by crosslinking and immunoprecipitation, measure exon-junction usage after acute depletion, and rescue with wild-type or selected RNA-binding/interface mutants. Use a minigene splicing reporter to mutate individual tracts, change their spacing or move them relative to a regulated exon, then confirm important effects at the endogenous locus. Assays of U2AF or U1 snRNP association and native spliceosomal assembly can reveal an early block; time-resolved splicing-intermediate analysis can reveal a late one. Control reporter transcription and precursor abundance, and account for nonsense-mediated decay, because an unstable mature isoform can conceal the splice choice that generated it. Mutants must retain expression and the intended remaining contacts. SXL supplies examples of both competition and late catalytic control; PTBP1 illustrates multivalent, context-dependent organization of splice-site recognition. RNA affinity is only one part of specificity.

I would test three separable claims: that a distinct assembly exists, that particular mRNAs are recruited or retained there, and that this recruitment causally alters their biological translation. Establishing one claim does not establish the others. In particular, a fluorescent punctum need not be a phase-separated liquid, and enrichment of untranslated RNA need not mean that the assembly caused repression.

Begin by tagging a candidate resident at its endogenous locus, verifying that the tagged protein retains its normal abundance and function. Identify additional resident proteins and RNAs with independent probes, assess ultrastructure or cell membrane exclusion where necessary, and follow assembly and dissolution over physiological time courses. Measure concentration dependence, partitioning and exchange rather than classifying the structure from roundness alone. fluorescence recovery after photobleaching reports mobility and exchange, but recovery can occur in non-liquid assemblies; fusion and rapid recovery are supporting observations rather than decisive tests. Avoid interpreting dissolution by 1,6-hexanediol as specific evidence, because it can perturb other cellular structures and processes. If phase separation is proposed, purified-component reconstitution should establish appropriate concentration, salt and RNA dependences, including sequence and valency controls and comparison with estimated cellular concentrations.

To identify recruited mRNAs, combine granule enrichment with RNA sequencing, controlling nonspecific recovery and input transcript abundance. Validate candidates by single-molecule fluorescence in situ hybridization using endogenous RNAs, negative-control RNAs and probes spanning different transcript regions. Three-dimensional segmentation and randomized spatial controls help distinguish genuine enrichment from chance overlap in a crowded cytoplasm. A useful RNA partition coefficient is $K_p=c_{\mathrm{in}}/c_{\mathrm{out}}$, estimated from molecule numbers and accessible volumes rather than uncorrected total intensity. A small assembly can have high concentration but contain only a small fraction of the cellular transcript, so report both enrichment and the fraction of molecules recruited.

Live imaging using an MS2- or PP7-tagged RNA can measure entry, exit, dwell time and transport relative to the assembly. Compare the labelled transcript with the untagged endogenous distribution: repeated hairpins, coat-protein binding and fluorescent-protein expression can alter processing or mobility. Track whole particles in three dimensions where possible to separate actual residence from transient passage through an imaging plane. A localization element identified in a candidate 3′ region can be deleted or transferred to a neutral reporter, with matched RNA abundance and integrity, to test sequence-dependent targeting. crosslinking and immunoprecipitation of the proposed recruitment factor then tests direct contact rather than mere colocalization.

biological translation should be measured on the same RNA molecules wherever possible. A reporter bearing RNA-label sites and an N-terminal repeated peptide tag, such as SunTag, makes an mRNA visible separately from its nascent chains. A bright nascent-chain focus at an RNA can report ongoing biological translation, while completed proteins diffuse away. Puromycin-mediated release and initiation-block/run-off controls validate the translation-dependent signal; tag maturation, antibody-fragment availability and altered peptide behaviour need controls. Fixed-cell protein abundance or a ribosomal-protein stain is inadequate: either can be present without active biological translation at the identified RNA.

This caution has experimental force. Single-molecule work by Daniel Mateju and colleagues showed that some stress-granule-associated mRNAs undergo biological translation, including complete biological translation cycles, rather than being obligatorily silent.^[ref] For the proposed new assembly, compare the probability and rate of biological translation before entry, during residence and after exit, with matched cytoplasmic molecules of the same transcript. If loss of biological translation consistently precedes recruitment, the assembly may sort previously repressed RNA. If recruitment precedes a reproducible biological translation change, that supports a different direction of action but still requires perturbation to exclude a common upstream cause.

Causality requires a perturbation that separates recruitment or condensation from other functions. Acutely deplete an assembly scaffold and rescue with wild-type protein or a separation-of-function variant that retains RNA binding and normal abundance but fails to assemble, or conversely assembles but cannot recruit the chosen RNA. Verify those properties directly. Studies of G3BP1/G3BP2-deficient biological cells showed that stress-granule assembly requirements depend on the initiating stress, motivating matched tests of the upstream stress response rather than assuming one knockout removes every granule type.^[ref] Measure global biological translation, stress signalling, RNA stability and biological cell viability alongside the local reporter. Loss of a granule accompanied by wholesale loss of biological translation machinery is not a specific test of granule function.

An orthogonal manipulation could inducibly recruit the same RNA to the assembly or release it, using inert recruitment controls and a non-condensing scaffold. Artificial clustering can itself obstruct biological translation, so this establishes conditional sufficiency only. Reversible manipulation and rescue, together with endogenous cis-element edits, provide stronger evidence. A convincing result connects a defined RNA-recruitment mechanism to a reversible biological translation change while preserving RNA abundance and upstream cellular state; phase behaviour and regulatory function should be concluded separately.

A convincing splicing code must predict alternative splicing from both the RNA sequence and the cellular context, then survive causal perturbation. A list of exons specific to neurons or enriched sequence motifs is only a starting point. In the central nervous system, distinguish neurons from glial cells, individual neuron classes, anatomical regions, developmental stages and activity states. Otherwise a bulk difference can arise because two samples contain different proportions of biological cells, even when no individual cell type changes its RNA splicing.

Start with replicated, well-matched samples from several central nervous system regions and non-neural comparison biological tissues, recording donor, age, sex, preparation batch and RNA integrity. Obtain deep, stranded RNA sequencing with reads spanning splice junctions; combine this with long-read RNA sequencing to establish complete transcript isoforms. Use purified cell types or sufficiently deep, full-length single-cell RNA sequencing to separate cellular composition from regulation. Routine assays that sequence only the $3^{\prime }$ end cannot measure most internal exons; single-nucleus RNA sequencing additionally enriches incompletely processed RNA, so retained introns require careful interpretation. A matched bulk or purified-cell dataset supplies coverage that sparse individual-cell observations lack.

Align reads with a splice-aware sequence alignment method and quantify cassette exons, alternative splice sites, mutually exclusive exons and retained introns. Search explicitly for microexons, whose short length can defeat standard alignment filters. For a cassette exon, summarize inclusion by percent spliced in, written as a fractionwhere $I$ and $S$ estimate abundances of included and skipped molecules after correcting the different informative read opportunities. Adding the two inclusion-junction counts and comparing their sum directly with a single skipping-junction count would bias this estimate. Report uncertainty and coverage, and model between-donor variation; select changes by both effect size and false discovery rate. Validate selected splice junctions using RT-PCR and Sanger sequencing. Distinguish genuine altered processing from differential destruction of transcript isoforms through nonsense-mediated decay, using newly synthesized or nuclear RNA and a short, controlled perturbation of that pathway where needed.

Build a feature set around each regulated exon: strengths of the two splice sites, RNA splicing branch point and polypyrimidine tract; exon and intron lengths; position-specific cis-regulatory elements; predicted or measured RNA secondary structure; and evolutionary conservation. Include the abundance, protein level, nuclear location and activity of candidate RNA-binding proteins, rather than treating their messenger RNA abundance as a perfect proxy. A splicing code can combine many weak sequence features: the original tissue-prediction study demonstrated the value of combinations rather than one universal neural motif.^[ref]

Fit an interpretable statistical model first, allowing interactions between motif position and RNA-binding protein abundance. Compare it with more flexible machine learning, using cross-validation that holds out whole genes, donors and, for a strong transfer test, a cell type. Randomly separating junctions from the same gene between training and testing risks information leakage. Compare against sequence-only, context-only and expression-matched baseline predictors. Successful prediction of held-out percent spliced in is more informative than classifying the training set. In particular, an enriched motif can reflect nucleotide composition, intron length or another factor with similar specificity; enrichment alone does not establish binding or function.

Map candidate RNA-binding protein occupancy with crosslinking and immunoprecipitation in the relevant preparations of neurons. Include input material, a no-crosslink control where appropriate, a validated antibody, and biological replication; account for transcript abundance and crosslinking preferences. Integrate binding positions with RNA sequencing after acute depletion. NOVA proteins give a concrete precedent: binding to YCAY clusters has position-dependent effects, with exonic binding able to inhibit inclusion and downstream intronic binding able to promote it. Here Y denotes a pyrimidine nucleobase. Thus the same motif can support opposite predictions at different positions.^[ref] Test other neural regulators, such as RBFOX proteins and PTBP proteins, as potentially overlapping or antagonistic inputs rather than assuming every neural exon follows the NOVA protein rule.

Finally, make the predictions experimentally vulnerable. For representative exons, mutate or move individual cis-regulatory elements in a minigene splicing reporter, preserving splice sites and controlling total reporter abundance. Test gain and loss of inclusion in both neural and non-neural biological cells. Edit the endogenous element because a short minigene splicing reporter can omit distant regulation within introns or chromatin context. Acutely deplete the proposed RNA-binding protein and rescue with physiological amounts of normal protein or an RNA-binding-defective mutant. Combined depletion tests redundancy; motif mutation plus factor depletion tests whether both act through the same element. A particularly strong result is the predicted reversal after moving a binding site from a repressive to an activating position. Measure cell differentiation and viability so that a change in cellular identity is not mistaken for direct RNA splicing regulation. The resulting code is a tested, context-dependent set of regulatory rules, with an explicit domain of validity.

Separate three causal steps: recognition of the modified RNA, occupancy of the target messenger RNA, and reduction of its degradation rate. Call the newly identified RNA-binding protein R. Its recovery in a screen need not mean it contacts the modified ribonucleotide directly; it could recognize a modification-dependent structure or arrive through another protein. Likewise, more target messenger RNA could reflect increased transcription rather than greater stability.

First reproduce the interaction using endogenous R and the endogenous target. Determine R's protein domains, expression and subcellular distribution, then use reciprocal RNA immunoprecipitation and crosslinking and immunoprecipitation to locate the occupied region. Normalize enrichment to input target abundance and R recovery, and include unrelated RNAs, a non-specific antibody and cells lacking R. Crosslink-based occupancy supports close contact, whereas recovery without crosslinking can preserve indirect complexes. Determine whether the relevant modification actually occurs near the binding site: mass spectrometry of purified target fragments can establish chemical identity, supplemented by a modification-specific mapping assay with known modified and unmodified standards. Bulk mass spectrometry of all cellular RNA cannot assign a modification to this particular transcript or position. Do not assume the modification is N6-methyladenosine merely because it is familiar.

Prepare short synthetic RNAs identical in nucleotide sequence, length, ends and labelling except for the single modified ribonucleotide. Measure binding of purified R over a concentration range by electrophoretic mobility shift assay or fluorescence anisotropy, with competition by unlabelled cognate and unrelated RNA. The dissociation constant distinguishes a quantitative preference from a binary pull-down impression. Verify that R is folded and sufficiently pure; include an RNA-binding-defective R mutant, several surrounding sequences and different modification positions. Modification-specific recovery from a cellular extract can disappear with purified R, revealing a missing partner rather than disproving the original screen.

Distinguish chemical recognition from structural recognition. Compare RNA secondary structure with and without the modification by RNA structure probing. Then disrupt the stem without changing the binding motif, or restore pairing through compensatory mutations. If an unmodified but constitutively exposed motif binds R, and restoring occlusion suppresses binding even when the modification remains, an RNA modification switch is plausible. Direct recognition is supported when modification discrimination persists after accessibility is matched and is lost upon a specific R binding-pocket mutation. Structural work can identify the contacts, but binding and structure controls remain essential. Modification-dependent exposure of a binding motif has an experimental precedent in the N6-methyladenosine-dependent RNA modification switch for HNRNPC.^[ref]

Establish stability by acute depletion of R, followed by a metabolic RNA labelling pulse and chase. Measure loss of labelled target molecules using appropriate spike-ins and a time course spanning the expected half-life, while independently estimating newly synthesized target RNA. SLAM-seq is one possible implementation: chemical treatment makes incorporated 4-thiouridine detectable through characteristic sequencing changes.^[ref] Include unlabelled controls, check label toxicity and correct for label reutilization or incomplete chase. When reporting molecules per biological cell, separate dilution through increasing cell number from chemical degradation. A transcription inhibitor time course provides an orthogonal check, but broad inhibition itself can change decay. Under a constant first-order degradation model, labelled molecules obeyA shorter half-life after R depletion, reversed by normal R but not its RNA-binding-defective mutant, establishes the proposed effect. Allow a more complex fit if the exponential decay model is inconsistent with the measured time course. At steady state, abundance is synthesis rate divided by degradation rate, so abundance alone cannot identify which rate changed.

Use a controlled target reporter gene carrying the occupied region, then remove or mutate that region and measure reporter messenger RNA decay. Preserve polyadenylation, RNA splicing and coding potential where possible, and distinguish site loss from altered RNA secondary structure. Manipulate the relevant modification-producing enzyme acutely, rescuing with normal or catalytically inactive enzyme; verify target-site modification after the manipulation. Cross the two perturbations: if R stabilizes the target specifically through the modification, removing the modification should reduce R occupancy and eliminate or substantially weaken the extra effect of removing R. This epistasis supports a shared pathway, but floor effects or redundant sites can obscure it. A site-specific chemically modified reporter helps separate local recognition from the many indirect consequences of removing a global modification enzyme.

Identify the affected decay step using poly(A) tail measurements, cap-state assays and mapping of decay intermediates. Test whether R excludes a microRNA-loaded Argonaute complex or a decay-promoting RNA-binding protein, blocks an endonuclease, inhibits deadenylation or decapping, or recruits a protective partner such as poly(A)-binding protein. Use protein interaction analysis with and without ribonuclease to distinguish RNA-bridged association from a more direct interaction. R mutants that retain target binding but lose a partner interaction separate recruitment from recognition. Depleting the implicated decay factor should suppress the destabilization caused by R loss; purified-system decay assays can test whether R alone physically protects the substrate.

Measure biological translation and subcellular location in parallel, using ribosome profiling or a controlled biological translation reporter and single-molecule fluorescence in situ hybridization. R might stabilize the target indirectly by altering ribosome loading or compartment access. Inhibiting biological translation can itself alter decay, and colocalization in a granule does not establish protection. The reported stabilizing action of IGF2BP proteins on modified targets provides a candidate mechanism to compare with, rather than an identity to assign to R.^[ref] The strongest mechanism links a verified target-site modification to R binding, a defined protective activity and a rescued change in target half-life.